v3.25.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 13,841 $ 25,030
Short-term investments 0 17,466
Restricted cash 146 146
Accounts receivable 8,875 1,482
Inventories 0 10,655
Other current assets 4,320 10,115
Total current assets 27,182 64,894
Property and equipment, net 285 1,294
Operating lease assets 31,727 39,807
Other assets 2,844 3,103
Total assets 62,038 109,098
Current liabilities:    
Accounts payable 1,384 4,367
Accrued compensation 4,599 6,589
Accrued research and development expenses 1,783 7,984
Deferred revenue 15,983 95,092
Other current liabilities 24,143 20,542
Total current liabilities 47,892 134,574
Deferred revenue - long-term 0 0
Operating lease liabilities - long-term 26,708 29,914
Liability related to the sale of future revenues - long-term 39,383 38,624
Other long-term liabilities 3,127 3,269
Total liabilities 117,110 206,381
Commitments and contingencies (Note 9)
Stockholders' equity (deficit):    
Common stock - $0.0001 par value, 500,000 shares authorized as of March 31, 2025 and December 31, 2024; 5,924 and 5,859 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 1 1
Additional paid-in capital 1,961,470 1,957,261
Accumulated other comprehensive (loss) income 0 8
Accumulated deficit (2,016,543) (2,054,553)
Total stockholders' equity (deficit) (55,072) (97,283)
Total liabilities and stockholders' equity (deficit) $ 62,038 $ 109,098

Source

10-Q
HTML PDF
XBRL
ZIP